Chondrogenic Potency Analyses of Donor-Matched Chondrocytes and Mesenchymal Stem Cells Derived from Bone Marrow, Infrapatellar Fat Pad, and Subcutaneous Fat. by Garcia, J et al.
Research Article
Chondrogenic Potency Analyses of Donor-Matched
Chondrocytes and Mesenchymal Stem Cells Derived from Bone
Marrow, Infrapatellar Fat Pad, and Subcutaneous Fat
John Garcia, Claire Mennan, Helen S. McCarthy, Sally Roberts,
James B. Richardson, and Karina T. Wright
ISTM, Keele University, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry,
Shropshire SY10 7AG, UK
Correspondence should be addressed to Karina T. Wright; karina.wright@rjah.nhs.uk
Received 22 July 2016; Accepted 4 September 2016
Academic Editor: Wesley N. Sivak
Copyright © 2016 John Garcia et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Autologous chondrocyte implantation (ACI) is a cell-based therapy that has been used clinically for over 20 years to treat cartilage
injuries more efficiently in order to negate or delay the need for joint replacement surgery. In this time, very little has changed
in the ACI procedure, but now many centres are considering or using alternative cell sources for cartilage repair, in particular
mesenchymal stem cells (MSCs). In this study, we have tested the chondrogenic potential of donor-matched MSCs derived from
bone marrow (BM), infrapatellar fat pad (FP), and subcutaneous fat (SCF), compared to chondrocytes. We have confirmed that
there is a chondrogenic potency hierarchy ranging across these cell types, with the most potent being chondrocytes, followed by
FP-MSCs, BM-MSCs, and lastly SCF-MSCs. We have also examined gene expression and surface marker profiles in a predictive
model to identify cells with enhanced chondrogenic potential. In doing so, we have shown that Sox-9, Alk-1, and Coll X expressions,
as well as immunopositivity for CD49c and CD39, have predictive value for all of the cell types tested in indicating chondrogenic
potency. The findings from this study have significant clinical implications for the refinement and development of novel cell-based
cartilage repair strategies.
1. Introduction
Autologous chondrocyte implantation (ACI) for the treat-
ment of focal chondral and/or osteochondral lesions has
changed very little since its inception [1], but there remains
scope for improvement. While we and others have reported a
significant level of improved joint function and a reduction
in pain following treatment with ACI [2–4], disadvantages
such as cost, potential donor-sitemorbidity, and the quality of
repair tissue formed remain. Althoughwe have shown donor-
site morbidity to be minimal [5], there is also the added risk
of chondrocyte dedifferentiation during culture expansion
[6, 7], the extent of which is likely to impact on the ability
of the chondrocytes to redifferentiate upon implantation into
the defect site.
Mesenchymal stem cells (MSCs) isolated from the bone
marrow (BM-MSCs) have been used in several clinical trials
as an alternative cell source for use in cell therapies to
treat cartilage injuries and osteoarthritis [8–10]. The process
of acquiring a sample of bone marrow, however, results
in an additional, painful procedure for the patient. The
infrapatellar fat pad (FP) is often routinely removed and
disposed of as surgical waste during arthroscopy or open knee
surgery and may provide an accessible alternative source of
MSCs (FP-MSCs) with demonstrable chondrogenic capacity
in vitro [11, 12]. Another accessible source of MSCs, although
studied to a lesser extent for their chondrogenic propensity,
is MSCs derived from subcutaneous fat (SCF-MSCs) [13, 14].
The ability to utilise these tissues for the treatment of cartilage
injuries has the potential to improve the way we currently
treat patients.
An important factor to consider when comparing and
contrasting the properties of different cell types is the “donor
impact” as donor demographics, such as age and gender, are
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Table 1: Donor demographics.
ID Gender Age (years) Pathology
Donor 1 Male 71 OA with extensive joint degeneration
Donor 2 Female 67 OA with loss of joint space
Donor 3 Female 75 Patellofemoral OA and loss of joint space in medial compartment
Donor 4 Female 81 OA
Donor 5 Male 74 OA with joint stiffness
factors which are known to affect cell proliferation and differ-
entiation capacity [15–17].The impact of donor is particularly
critical for autologous treatment regimes and in deciding
whether such a cell-based therapy represents the appropriate
treatment option for an individual patient. Unravelling the
impact of tissue and donor source and developing tools to
predict the efficacy of cell-based treatments will likely result
in the refinement of existing treatments and may provide
valuable additional information for consideration during
the decision making process of cost benefit versus clinical
efficacy.
In this study, we have examined 4 different cell types
(chondrocytes, BM-MSCs, FP-MSCs, and SCF-MSCs) and
tested the chondrogenic potential of each population of
cells. This study compares donor-matched cell types and was
designed to establish the impact of tissue source and donor
on chondrogenic differentiation capacity and to continue the
process of establishing a marker panel indicative of chon-
drogenic potency and likely clinical success. Such marker(s)
could be screened for and used in the selection of a partic-
ular cell type and/or subpopulation of cells with enhanced
chondrogenic capability prior to treatment. We envisage that
taken together this information could significantly improve
the success of cell-based therapies for cartilage injuries and
perhaps even lead to the development of novel individualised
treatments for cartilage repair.
2. Materials and Methods
2.1. Patients. All samples were obtained after patients had
provided written informed consent; favourable ethical ap-
proval was given by the National Research Ethics Ser-
vice (11/NW/0875) and all experiments were performed in
accordance with relevant guidelines and regulations. Donor-
matched samples of cartilage, BM, FP, and SCFwere obtained
from 5 patients (2 males and 3 females, ages 67–81 years)
undergoing total knee replacement (TKR) surgery (Table 1).
2.2. Isolation of Chondrocytes. Macroscopically normal artic-
ular cartilage was excised from the femoral condyles of
patients undergoing TKR. Cartilage tissue was weighed,
minced into small pieces with a sterile scalpel, and digested
in collagenase type II (250 IU/mg dry weight, Worthington,
New Jersey, USA) for 16 hours at 37∘C.The resulting suspen-
sionwas passed through a 40𝜇mcell strainer and centrifuged
(350×g for 10 minutes) to produce a cell pellet that was
resuspended in Dulbecco’s Modified Eagle’s Medium/F-12
(DMEM/F-12) with 1% (v/v) penicillin/streptomycin (P/S)
and 10% (v/v) foetal calf serum (FCS, all Life Technolo-
gies, Paisley, UK), hereafter referred to as complete culture
medium, at a seeding density of 5 × 103/cm2.
2.3. Isolation of MSCs from Bone Marrow. Bone marrow as-
pirates and bone chips were obtained from the tibial plateau
of patients undergoing TKR. Bone marrow was first diluted
with an equal volume of phosphate buffered saline (PBS, Life
Technologies) then split between two 50mL tubes, layered
onto 10mL of Lymphoprep (Alere Technologies AS, Oslo,
Norway), and centrifuged (900×g for 20 minutes). The buffy
coat, containing mononuclear cells, was aspirated and added
to complete culture medium and centrifuged (750×g for
10 minutes). The resulting cell pellet was resuspended in
complete culture medium and BM-MSCs were seeded at a
density of 20 million cells per 75 cm2 tissue culture flask.
Cells were left to adhere for 24 hours before the media were
changed and the nonadherent cells were removed. Bone chips
were placed in a 175 cm2 culture flask with 30mL of complete
media for 7 days to allow the plastic adherent cells to migrate
out of the bone chips.
2.4. Isolation of MSCs from Adipose Tissues. Human FP and
SCF tissue samples were obtained from patients and pro-
cessed within 2 hours of receipt from the operating theatre.
The FP was dissected from the innermost zone, to avoid
contamination with synovium derived cells as described
previously [12]. Dissected FP and SCF tissues were washed
in PBS, minced, and digested with 1mg/mL collagenase type
I (≥125 digesting units/mg, Sigma-Aldrich, Poole, UK) in
serum-free media for 1 h at 37∘C. The resulting cells were
strained through a 40𝜇m nylon cell strainer and centrifuged
(350×g for 10min). Cells were then seeded at a density of
5 × 10
3/cm2 in complete culture medium. All cultures were
maintained in a humidified incubator at 37∘C and 5% CO
2
.
2.5. RNA Extraction and Quantitative Real-Time Polymerase
Chain Reaction (qRT-PCR). After trypsinisation at passages
3-4, 2 × 105 monolayer cells were centrifuged (500×g
for 5 minutes), frozen in liquid N
2
, and stored at −80∘C
briefly prior to extraction. Cells were thawed on ice and
messenger RNA (mRNA) was extracted using an RNeasy
extraction kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. RNA was converted to
cDNA using a High-Capacity cDNA Reverse Transcriptase
Kit (Applied Biosystems, Warrington, UK) according to the
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manufacturer’s instructions. qRT-PCR was used to evaluate
the expression of specific genes, indicative of chondrogenic
potency or hypertrophy [18]. RT-qPCR analysis was per-
formed on the Quant Studio 3 Real-Time Quantitative PCR
System (Applied Biosystems) using SYBR green QuantiTect
primer assays for the chondrogenic genes Sox-9, collagen
type II (Coll II), aggrecan (ACAN), frizzled-related protein
(FRZB), and the following genes indicative of hypertrophy:
activin receptor-like kinase 1 (Alk-1) and collagen type X
(Coll X). Peptidylprolyl isomerase A (PPIA) and TATA-
binding protein (TBP) were used as reference genes (Qiagen).
The relative expression of each genewas determined using the
comparative CT method [19].
2.6. Flow Cytometry. Flow cytometry was used to assess the
immunoprofile of chondrocytes andMSCs prior to chondro-
genic differentiation. Cells at passages 3-4 were harvested,
pelleted, and resuspended in 2%bovine serumalbumin (BSA,
Sigma-Aldrich) in PBS. FC receptors were blocked for 1 h at
4∘C using 10% (v/v) human IgG (Grifols, Barcelona, Spain)
in 2% (v/v) BSA in PBS (immunobuffer). The cells were
then washed with immunobuffer and centrifuged (350×g
for 8minutes). Cells were stained for 30minutes at 4∘C
with fluorochrome conjugated antibodies against cell surface
markers indicative of MSC according to the International
Society for Cellular Therapy (ISCT) [20]. Markers probed
for were CD90-phycoerythrin (PE) (clone 5E10), CD105-
allophycocyanin (APC) (clone 266), and CD73-brilliant vio-
let 421 (BV421) (clone AD2), CD19-BV421 (clone HIB19),
CD34-APC (clone 581), CD45-PE (clone HI30), HLA-DR-
APC (clone TU36), and CD14-PerCP-Cy5.5 (clone M𝜙P9).
CD markers which have been reported as putative chondro-
genic potency markers [21–28] were also probed for; these
included CD49c-PE (clone C3 II.1), CD166-BV421 (clone
3A6), CD39-APC (clone TU66), CD44-peridinin chloro-
phyll protein-cyanine 5.5 (PerCp-Cy5.5) (clone G44-26), and
CD271-BV421 (clone C40-1457) (BD Biosciences). Appro-
priate isotype-matched IgG controls were used throughout
(BD Biosciences). Data from at least 10,000 stained cells is
presented which was analysed using a FACSCanto II flow
cytometer (BDBiosciences) and BD FACSDiva v.7.0 software.
2.7. Chondrogenic Differentiation. The chondrogenic poten-
tial of all cultured cell populations was assessed at passage
4 using an established 3D pellet culture system [12, 29].
Briefly, 2 × 105 cells were centrifuged to produce a cell pellet
which was maintained in DMEM F12, FBS (10% v/v), P/S
(1%) ITS (1%, v/v), ascorbic acid (0.1mM) (Sigma-Aldrich),
dexamethasone (10 nM), and transforming growth factor 𝛽-1
(TGF-𝛽1, PeproTech, London,UK) (10 ng/mL). After 28 days,
cell pellets were frozen in liquid nitrogen and stored at −80∘C
prior to use. In total, 𝑛 = 6 pellets per donor were produced,
𝑛 = 3 for glycosaminoglycan (GAG)/DNA analysis and 𝑛 = 3
for histological analysis.
2.8. GAG/DNA Analysis of Chondrogenic Pellets. Pellets were
digested using papain to release GAGs and DNA. A digestion
buffer consisting of 50mM sodium phosphate (BDH), 2mM
EDTA (Sigma-Aldrich), and 20mMN-acetyl cysteine (BDH)
was prepared and the pH adjusted to 6. Papain (Sigma-
Aldrich) was added to the digestion buffer to reach a final
concentration of 125𝜇g/mL. Each chondrogenic pellet was
digested using 200𝜇L of papain digest solution and placed in
a 60∘C oven for 3 hours. The digest suspensions were mixed
vigorously every 30 minutes by vortexing the tubes. Samples
were then centrifuged at 1000×g for 5mins, aliquoted, and
stored at −20∘C until further use.
The dimethylmethylene blue (DMMB) assay was used
to quantitate GAGs [30, 31]. Standards were prepared by
dissolving chondroitin sulphate (Sigma-Aldrich) frombovine
trachea in PBS to create appropriate serial dilutions. Fifty
microlitres of sample or standard was added in triplicate to
a 96-well plate and 200𝜇L of the DMMB staining solution
was added to each well. The absorbance was immediately
read at 𝐴530 nm and 𝐴590 nm. A standard curve was plotted
(𝐴530 nm/𝐴590 nm) − (𝐴530 nmblank/𝐴590 nmblank), from which
the total GAG content in each sample was calculated using
the equation of the curve.
The PicoGreen fluorescence assay (Invitrogen) was used
to quantitate the amount of double stranded DNA in solution
and was conducted according to the manufacturer’s instruc-
tions. Fluorescence was read on a plate reader configured to
excitation = 480 nm and emission = 520 nm. The normalisa-
tion of GAG content in chondrogenic pellets was achieved by
dividing the total GAG content of a given pellet by the DNA
content of that same pellet.
2.9. Histological Analysis of Chondrogenic Pellets. Pellets were
cryosectioned (7 𝜇m) onto poly-L-lysine coated slides (Cell
Path, Newtown, UK) and stained for GAGs with toluidine
blue (BDH) metachromatic stain for 30 seconds and then
washed briefly in tap water. Slides were left to air dry before
mounting in Pertex (Cell Path). Chondrogenic pellets were
assessed following toluidine blue staining using a modified
version of the Bern score [32]. In brief, cells pellets were
assessed using the following criteria: uniformity and intensity
of toluidine blue staining and distance between cells/amount
of matrix produced and cell morphology. Each of these three
categories was scored from 0 to 3.
2.10. Statistical Analysis. TheShapiro-Wilk normality test was
used to assess the distribution of quantitative data. A one-
wayANOVAwith Bonferroni’smultiple comparisons test was
used to test for significant differences between cell types with
regard to gene expression, immunoprofile, GAG quantita-
tion, and histological scores for chondrogenic pellets. Pear-
son’s correlation coefficients were determined for gene-gene
expression analyses and chondrogenic assessments (GAG
quantitation and histological analyses). Multilevel modelling
was conducted to determinewhether gene expression and cell
surface marker positivity were predictors of chondrogenic
outcome asmeasured by GAG content of the pellet and histo-
logical scoring. In these models, cell source, gene expression,
and cell surface marker positivity were considered as fixed
effects, while the donor was considered as a random effect.
The donor effect was determined using Wald’s tests. Graphs
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Figure 1: The expression of chondrogenic and hypertrophic genes in monolayer cell populations prior to chondrogenesis. ((a)–(f))
Chondrocytes (Ch), bonemarrowMSC (BM), fat padMSC (FP), and subcutaneous fat MSC (SCF). Data shown are themeans ± the standard
deviation of triplicate runs and 5 donors for each cell population. One-way ANOVA and post hoc Bonferroni tests were used to test for
significant differences in gene expression levels between cell types. (g) Pearson’s correlation analysis matrix comparing genes which may be
predictive of chondrogenic potential; significant correlations are in bold. Gene expression is expressed relative to the reference genes PPIA
and TBP.
are shown as means ± standard deviation, with statistical
significance considered at ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 <
0.001. All statistical analyses were performed in GraphPad
Prism version 6 (GraphPad Software, California, USA) and
SPSS version 20 (IBM, New York, USA).
3. Results
3.1. Chondrogenic/Hypertrophic Gene Expression prior to
Chondrogenic Differentiation. Perhaps not too surprisingly,
of the cell types tested in this donor-matched study, the
chondrogenic potency genes (Sox-9, Coll II, aggrecan, and
FRZB)were consistently expressed at the highest levels in cul-
ture expanded chondrocytes. Further, chondrocytes demon-
strated the lowest expression profiles for the hypertrophic
genes tested (Alk-1 and Coll X). Of the MSC populations
that we have examined, BM-MSCs displayed chondrogenic
and hypertrophic profiles that most closely resembled those
of culture expanded chondrocytes. In contrast, the adipose
sources of MSCs investigated (FP-MSCs and SCF-MSCs)
were least like culture expanded chondrocytes and demon-
strated the lowest chondrogenic potency and the highest
hypertrophic gene expression profiles. SCF-MSCs expressed
Alk-1 at significantly higher levels than chondrocytes and
BM-MSCs (𝑝 = 0.044 and 𝑝 = 0.034, resp.) (Figures 1(a)–
1(f)).
Gene expression associations for all of the cell types
examined in this study were tested using Pearson’s correla-
tion coefficient analyses and are presented in a correlation
matrix (Figure 1(g)). Significant interactions noted between
the chondrogenic potency genes were as follows: aggrecan
Stem Cells International 5
Percentage of positive cells (mean% ± SD)
Markers
Chondrocytes BM-MSCs FP-MSCs SCF-MSCs
CD73 91.2 (±17.7) 87.1 (±18.0) 99.9 (±0.1) 99.9 (±0.0)
CD90 98.0 (±3.8) 96.4 (±2.5) 99.9 (±0.0) 99.9 (±0.1)
CD105 99.4 (±0.7) 96.7 (±4.1) 98.1 (±4.1) 99.9 (±0.1)
CD34 9.5 (±8.0) 5.1 (±5.4) 74.5 (±15.6) 62.2 (±20.8)
CD45 1.5 (±0.6) 1.3 (±0.4) 2.4 (1.3) 1.6 (±0.6)
CD14 20.4 (±27.1) 14.8 (±12.0) 17.9 (±36.5) 21.4 (±39.3)
CD19 1.3 (±0.8) 2.0 (±1.2) 1.4 (±0.6) 1.6 (±0.5)
HLA-DR 1.4 (±0.6) 1.3 (±0.8) 1.7 (±0.7) 1.3 (±0.6)
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Figure 2: Immunoprofiles for MSC markers and putative chondrogenic potency markers of culture expanded cells prior to chondrogenesis.
(a) ISCTMSC immunoprofiles. Immunoprofiles for the putative chondrogenicmarkers CD49c (b), CD166 (c), and CD39 (d). Flow cytometry
was used to detect the percentage of positive cells for each marker on monolayer cell populations of chondrocytes (Ch), bone marrow MSC
(BM), fat pad MSC (FP), and subcutaneous fat MSC (SCF) prior to chondrogenesis. Data shown are the means ± the standard deviation of 5
donors for each cell population. One-way ANOVA and post hoc Bonferroni tests were used to test for significant differences in the positivity
of cell surface markers between cell types.
was positively associated with Sox-9, Coll II, and FRZB; in
addition, Sox-9 was positively associated with Coll II. There
was also a significant negative association observed between
Coll II and Alk-1 expression.
3.2. MSC/Chondrogenic Immunoprofiling. Flow cytometry
analyses revealed immunopositivity for the MSC markers
CD73, CD90, and CD105 for all of the populations of cells
examined, but to varying levels. FP and SCF derived MSCs
adhered to ISCT criteria (i.e., >95% positive); chondrocytes
and BM-MSCs also adhered to ISCT criteria for CD90 and
CD105 positivity but were <95% positive for CD73. All of the
cell populations tested were <2% positive for CD19, CD45,
and HLA-DR, in line with ISCT criteria. Some positivity
was recorded in all of the cell populations tested for CD34
with high levels (62.2–74.4% positivity) seen in the adipose
derived MSCs, which also adheres to ISCT [33]; in addition,
>2% of BM-MSCs were also CD34 positive, which does not
conform to recommendations by the ISCT [20]. CD14 was
present on all cell populations, ranging on average between
14.8 and 21.4% positivity for each cell type (Figure 2(a)).
Differences between cell types for putative chondrogenic
potency marker positivity were noted for CD49c, CD166,
and CD39 (Figures 2(b)–2(d)). Chondrocytes showed sig-
nificantly greater positivity for CD49c compared to SCF-
MSCs (𝑝 = 0.014), whereas the adipose derived MSCs
showed significantly higher positivity for CD166 compared
to chondrocytes or BM-MSCs (𝑝 = 0.0046 and 𝑝 = 0.0002,
resp., for FP-MSCs and 𝑝 = 0.021 and 𝑝 = 0.01, resp., for
SCF-MSCs). No differences were noted for CD44 or CD271,
in that all cell types were >95% positive for CD44 and <5%
positive for CD271 (data not shown).
3.3. Chondrogenic Differentiation. After 28 days of differ-
entiation, donors demonstrated variability in chondrogenic
capacity across the cell types tested. When results from
individual donors were examined, chondrocytes consistently
produced chondrogenic pellets in terms of GAG quan-
titation and histological analyses, but the propensity for
MSCs to undergo chondrogenic differentiation was variable
between individuals. GAG/DNA analyses appeared to match
the histological findings noted for each patient: that is,
larger pellets with prominent matrix metachromasia had
the highest levels of GAGs measured (Figure 3). Pearson’s
correlation analyses across donors confirmed that there was a
significant association between pellet GAG quantitation and
histological score (𝑝 = 0.01). When donors were grouped
and chondrogenic analyses were performed comparing dif-
ferentiation between cell types, chondrocytes consistently
demonstrated the most pronounced chondrogenic differ-
entiation in terms of GAG/DNA analyses; they produced
significantly more GAG than BM and SCF derived MSCs
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Figure 3: Chondrogenic assessments of pellet cultures between donors. (a) Production of GAG/DNA in pellet cultures from chondrocytes
(Ch), bonemarrowMSC (BM), fat padMSC (FP), and subcutaneous fatMSC (SCF). GAGs weremeasured after chondrogenic differentiation
using the DMMB assay and normalised to the DNA content of pellets; each donor is represented in individual graphs. Data shown are the
means ± the standard deviation of triplicate pellets. (b) Chondrogenic pellets from Ch, BM, FP, and SCF showing representative toluidine
blue staining for each donor. Scale bars represent 200 𝜇m.
(𝑝 = 0.032 and 𝑝 = 0.030, resp., Figure 4(a)). In terms of
histological quantitation and chondrogenic score SCF-MSC
scores were significantly lower than chondrocytes, BM, and
FP derived MSCs (𝑝 < 0.0001, 𝑝 = 0.0195, and 𝑝 =
0.0082, resp.) and chondrocytes scored significantly higher
than BM-MSCs (𝑝 = 0.013, Figure 4(b)). Chondrocytes also
produced the largest pellets (in terms of diameter) compared
to any of the MSCs tested (𝑝 < 0.0001) and FP-MSC pellets
were significantly larger than SCF-MSC pellets (𝑝 = 0.008,
Figure 4(c)).
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Figure 4: Chondrogenic assessments of pellet cultures across cell types. (a) Production of GAG/DNA in pellet cultures from chondrocytes
(Ch), bone marrow MSC (BM), fat pad MSC (FP), and subcutaneous fat MSC (SCF) for all donors combined. (b) Chondrogenic histology
scores for Ch, BM, FP, and SCF for all donors combined. (c) Mean chondrogenic pellet diameter (𝜇m) for Ch, BM, FP, and SCF for all donors
combined. Data shown are the means ± the standard deviation of triplicate pellets and 5 donors for each cell population. One-way ANOVA
and post hoc Bonferroni tests were used to test for significant differences between cell types.
3.4. Chondrogenic Potency Analyses. Multilevel modelling
analysis was performed in an effort to identify chondrogenic
potency predictors prior to chondrogenic differentiation.
This analysis demonstrated that Alk-1 expression and CD166
immunopositivity both negatively associated with GAG
quantitation in pellet cultures. However, CD49c and CD39
expression positively associated with GAG quantitation and
histological score, respectively. Sox-9 expression positively
associated with chondrogenic histological score, whereas
expressions of the hypertrophic genes Coll X and Alk-1 were
shown to negatively associate (Table 2).
Further multilevel model analysis showed that cell type
(but not donor source) had a significant impact on the pre-
dictive aspect of gene expression for both of the chondrogenic
assessments tested, that is, GAG quantitation (𝑝 < 0.001) and
histological outcome (𝑝 < 0.001). Similarly, cell type (but
not donor source) had a significant impact on the predictive
aspect of cell surface marker positivity with regard to both
GAG quantitation (𝑝 < 0.001) and histological outcome
(𝑝 < 0.001). Using an interaction term in a multilevel model
consisting only of the cell types and the variable in question,
results showed that the relationship between Sox-9/Alk-1
expression and the histological outcome varied significantly
across cell source (𝑝 = 0.03 and 𝑝 = 0.034, resp.), which was
not the case for Coll X (𝑝 = 0.07). The relationship between
Alk-1 expression and GAG quantitation also did not vary
across cell types (𝑝 = 0.43). In terms of immunopositivity,
the relationship between CD39 positive cells and histological
outcome varied significantly between cell types (𝑝 < 0.001) as
did the relationship between CD49c or CD166 positive cells
and GAG quantitation (𝑝 < 0.001 for both markers).
4. Discussion
In recent years MSCs isolated from BM, FP, and SCF have
been compared and contrasted extensively in in vitro studies
[12, 13, 34–38] as alternative cell sources to the chondrocytes
used in ACI. However, to our knowledge there are no studies
to date that have compared the in vitro chondrogenic potency
of these cell types together and from matched samples. In
the present study, we have tested known gene profiles and
immunoprofiles indicative of chondrogenic potential in a
predictive model comparing chondrocytes, BM, FP, and SCF
derived MSCs from 5 matched human donors. We have
determined the expression of the chondrogenic genes, Sox-
9, Coll II, ACAN, and FRZB, and the hypertrophy associated
genes, Coll X and Alk-1, in these cell populations prior to
chondrogenesis. In doing so, we have confirmed that across
all of the cell populations tested, the master regulator of
chondrogenesis, Sox-9, correlates with the expression of Coll
II and ACAN and that the hypertrophy associated marker
Alk-1 is negatively associated with Coll II expression. In
addition, we have shown that there is a positive association
between the expression of FRZB and ACAN, which has been
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Table 2: Multilevel modelling.
GAG/DNA Chondrogenic histology score
Coefficient 95% CI 𝑝 values Coefficient SE (95% CI) 𝑝 values
Sox-9 −5.6 −11.7, 0.5 0.07 1.01 0.18, 1.84 0.02
Coll II 22.3 −7.8, 52.4 0.14 3.96 −0.16, 8.08 0.06
Aggrecan −0.003 −0.2, 0.2 0.97 −0.019 −0.04, 0.004 0.10
FRZB 33.1 −27.4, 93.6 0.3 0.86 −7.46, 9.18 0.83
Coll X −0.01 −0.02, 0.003 0.12 −0.002 −0.004, −0.0002 0.03
Alk-1 −9.5 −12.2, 6.7 <0.001 −0.61 −0.99, −0.23 0.003
CD49c 0.2 −0.1, 0.5 0.018 −0.04 −0.02, −0.01 0.63
CD166 −0.3 −0.5, −0.04 0.03 0.01 −0.04, 0.034 0.16
CD39 −0.02 0.01, 0.4 0.78 0.024 0.01, 0.04 0.002
Significant associations are indicated in bold.
previously reported in the chondrogenic ATDC5 cell line
[39]. In terms of immunoprofile, the putative chondrogenic
markers CD44, CD105, and CD271 were excluded from
predictive analyses due to their uniform expression levels
across cell types. CD49c, CD166, and CD39 were present on
all of the cell populations examined to varying degrees and
as such were taken forward into our multilevel chondrogenic
potency analysis.
Following an established in vitro cell pellet chondrogenic
differentiation procedure [12, 29] our quantitative assessment
of GAG synthesis demonstrated that chondrocytes generate
significantly more GAGs compared to BM-MSCs and SCF-
MSCs but not FP-MSCs,with somenotable variation between
donors. Our findings are comparable to previous studies
which have shown that chondrocytes and FP-MSCs display
similar levels of GAG production and that FP-MSCs produce
more GAGs than BM-MSCs [37] and donor-matched SCF-
MSCs [38]. Further, our assessments for chondrogenic differ-
entiation status in terms ofGAGquantitation andhistological
score were significantly correlated. Chondrocyte-generated
pellets consistently produced the highest scores, which were
significantly greater than those formed by BM or SCF cell
populations, whereas SCF pellets produced the lowest scores
of all the cell populations examined. By simply measuring
the diameter of pellets we have also shown that chondrocytes
produced the largest pellets compared to BM and SCF
derived pellets. Taken together, our chondrogenic assess-
ments suggest that, not too surprisingly, culture expanded
chondrocytes have the greatest propensity for chondrogenic
differentiation in vitro, closely followed by FP-MSCs and
then BM-MSCs, whereas SCF-MSCs consistently produced
the worst chondrogenic outcome measures, regardless of the
assessment used. These findings are corroborated by other
studies that have reported paired comparisons between these
cell types [12, 13, 34–38]. However, this is the first time, to
our knowledge, that all four of these cell populations have
been examined in the same study, allowing for a hierarchical
chondrogenic potency comparison with the impact of donor
taken into account by donor matching the samples tested.
The multilevel modelling analyses performed in this
study have allowed us to explore the relationships between
putative chondrogenic potency markers (gene expression
and surface marker profiles) and chondrogenic outcome
based on combined data from each cell source tested, while
simultaneously examining the potential influence of donor
and cell type. However, we have not yet verified whether the
predictive factors for chondrogenesis that we have identified
for combined data are present if only individual cell types are
analysed as we believe that the small donor size precludes this
type of analysis in the present study. We should of course
be cautious when interpreting any analyses derived from
a small donor sample size and we acknowledge this as a
limitation of the study. Nonetheless, ourmultilevel modelling
has revealed that the expressions of Alk-1 and Coll X are
negatively associated with chondrogenic potential in terms
of histology scores and for Alk-1 expression, as well as the
GAG content of chondrogenically induced pellet cultures. In
contrast, Sox-9 expression prior to chondrogenesis positively
correlated with histological pellet scores. Some of these gene
associations match a previous report comparing FP-MSCs
and SCF-MSCs [38]. The novelty of our study is that some
of these chondrogenic potency gene associations hold true
across all of the cell types examined in the present study. The
poor correlation between the baseline (predifferentiation)
expressions of the chondrogenic genes Coll II and ACAN
is noteworthy and comparable to findings in other studies
[40, 41]. For example, Stenberg et al. (2014) have confirmed
that the transplanted chondrocyte expression levels of ACAN
and Coll II in ACI had no bearing on clinical outcome [40].
Further, Cote et al. (2016) demonstrated that the genome-
wide transcription profile of Coll II and ACAN (amongst
other genes) did not correlate with the production ofGAGs in
a single cell analysis of bovine MSCs and chondrocytes. The
authors attribute this finding to the heterogeneity in single
cell transcriptional profiles. It is extremely likely that the gene
analysis in the present study derived from heterogeneous cell
populations and four very different tissue sources will vary to
an even greater extent.
In addition, our multilevel analysis indicates that CD49c
and CD39 immunopositivity positively predicts GAG pro-
duction and histological score, respectively, in cell pellets,
with no significant difference observed between donors.
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Other studies have shown that CD49c positivity on chon-
drocytes and CD39 positivity on synovium derived MSCs
are associated with increased in vitro chondrogenic potential
[21, 27]; however, our results are the first to demonstrate
these relationships across matched chondrocytes, BM-MSCs,
and adipose derived MSCs. Perhaps surprisingly CD166
positivity did not indicate chondrogenic potential, as has
been previously shown [24, 26]; in fact immunopositivity
for this marker was negatively associated with chondrogenic
assessments. One potential explanation for this findingmight
be that CD166 was expressed at significantly greater levels
on SCF-MSCs compared to chondrocytes and BM-MSCs
and that in our hands SCF-MSCs have been shown to
consistently demonstrate a poor propensity for chondrogenic
differentiation. Interestingly, we have demonstrated through
this multicell type, donor-matched study that the source
of cells significantly influences both GAG production in
pellet culture and also the histological score of the pellet. In
contrast, the donor had no demonstrable impact on either
of the chondrogenic assessments tested, although as stated
previously we must be cautious with this finding as our
results are based on a small cohort of donors. Follow-up
studies should be geared towards understanding the molec-
ular mechanisms that account for the differences observed
between cell populations and in the development of methods
to select cells with enhanced chondrogenic potential.
5. Conclusions
We have demonstrated the chondrogenic predictive value
of high levels of Sox-9 and low levels of collagen type X
or Alk-1 expression as well as immunopositivity for CD49c
and CD39 in a combined data analysis of chondrocytes,
BM-MSCs, FP-MSCs, and SCF-MSCs. Further individual
analyses on larger donor cohorts will be required to validate
these findings for individual cell types before these predictive
factors could be used as selection criteria prior to the
transplantation or banking of each cell type in the treatment
of cartilage injuries. We have also shown, using donor-
matched samples, that cell type significantly influences the
chondrogenic potency of the MSC sources examined in this
study; we have demonstrated that MSCs sourced from the
infrapatellar fat pad of the knee or bone marrow provide the
“next best” alternative to chondrocytes, in terms of in vitro
chondrogenic differentiation capacity. Further, our results
have consistently shown that SCF derived MSCs have the
poorest propensity for chondrogenic differentiation. These
findings have important clinical implications, not only for the
understanding ofMSC chondrogenic differentiation capacity,
but also for the development of cell therapy strategies to
screen for and select potent cell types prior to application in
the treatment of cartilage injuries.
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